Fara Brasó‐Maristany

Author

Also Known As

Adamo, Barbara, Aleix Prat, Bellet, M., Braso-Maristany, Fara, Cejalvo, Juan Miguel, Chic, N, Conte, P, F Brasó Maristany, F Brasó-Maristany, F. Braso Maristany

308

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Vall d'Hebron Institute of Oncology Universitat de Barcelona University of North Carolina at Chapel Hill

About

Fara Brasó‐Maristany is an author at Hospital Clínic de Barcelona specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	538
2	Cell Biology	2	2	262
3	Engineering	1	1	60
4	Health Sciences	1	1	59
5	Nursing	1	1	72

Fara Brasó‐Maristany

Publications

Citations

H-Index

Page 1

	Year	Citations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, npj Breast Cancer	2021	655
Frequency and spectrum of PIK3CA somatic mutations in breast cancer Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Breast Cancer Research	2020	357
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer Fara Brasó‐Maristany, Simone Filosto, Steven Catchpole, Nature Medicine Breast OncologyOncologyMedicineTumor GrowthPim1 Kinase	2016	238
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade Aleix Prat, Tomás Pascual, Carmine De Angelis, JNCI Journal of the National Cancer Institute	2019	163
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies Aleix Prat, Anwesha Chaudhury, Nadia Solovieff, Journal of Clinical Oncology	2021	139
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer Aleix Prat, Valentina Guarneri, Tomás Pascual, EBioMedicine	2022	133
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer Marta Palafox, Laia Monserrat, Meritxell Bellet, Nature Communications	2022	113
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade Fara Brasó‐Maristany, Gaia Griguolo, Tomás Pascual, Nature Communications	2020	105
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease Susana García‐Recio, Aatish Thennavan, Michael P. East, Journal of Clinical Investigation	2020	99
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation Aleix Prat, Valentina Guarneri, Laia Paré, The Lancet Oncology NursingPrognostic EvaluationExternal EvaluationBreast OncologyMedicine	2020	72

Page 1